Equities Analysts Set Expectations for TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Bloom Burton lifted their Q3 2025 earnings per share estimates for shares of Medexus Pharmaceuticals in a research note issued on Thursday, January 23rd. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.10 per share for the quarter, up from their prior estimate of $0.04. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.17 EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.69 EPS.

A number of other research firms also recently commented on MDP. Stifel Nicolaus boosted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday, January 8th. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Finally, Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Medexus Pharmaceuticals has an average rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Performance

TSE:MDP opened at C$4.92 on Monday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm’s 50-day simple moving average is C$3.25 and its 200 day simple moving average is C$2.72. The firm has a market cap of C$120.69 million, a price-to-earnings ratio of 98.40 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.